A Supramolecular Material for Controlling Kiwifruit Bacterial Canker
Advanced Science · 2025-08 · 12 (31)
DOI: 10.1002/advs.202414752 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 24.05.2025. Verfasst von Xile Deng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Academy of Agricultural Sciences, Changsha, 410125, China. Hauptthemen laut MEDLINE: Actinidia, Anti-Bacterial Agents, Plant Diseases, Pseudomonas syringae. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Science and Technology Innovation Committee, National Natural Science Foundation of China, Science and Technology Innovation Program of Hunan Province.
Abstract (Originalsprache)
Kiwifruit, a nutritious fruit consumed globally, is affected by kiwifruit bacterial canker (KBC) caused by Pseudomonas syringae pv. actinidiae ( Psa ), which is a major biotic stress that adversely impacts its cultivation and production. KBC control is still challenging owing to the evolution of resistant populations of Psa , the environmental risks associated with copper bactericides, and lack of effective bactericides. Therefore, to develop novel and efficient bactericides against Psa , a matrine (MT)‐5‐methylsalicylic acid (5‐OMESA) salt (MOS) is synthesized and its antibacterial activity is analyzed. The newly synthesized compound is more antibacterial against Psa than the commercial bactericide thiazole copper (TC). MOS significantly disrupts the membrane structure of Psa and penetrates the cells more efficiently. In addition, it has high affinities to the Psa FtsZ protein and DNA helicase, which probably contribute to its bactericidal activity. Subsequently, the encapsulation of MOS into a supramolecular nanocarrier hydroxypropyl‐β‐cyclodextrin (HPCD) and the fabrication of a nano formulation (MOS@HPCD) result in superior solubility, penetration, foliar deposition and wettability, sustained release, and prolonged protection against Psa . The in vitro and in vivo control efficiencies of MOS@HPCD against Psa are markedly enhanced compared to those of MOS. This study proposes a promising supramolecular material to control KBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hunan Academy of Agricultural Sciences, Changsha, 410125, China.
- National Pesticide Engineering Research Center (Tianjin), College of Chemistry, Nankai University, Tianjin, 300071, China.
- Department of Chemistry, College of Sciences, Northeastern University, Shenyang, 110819, China.
- Department of Neurology, Hunan Academy of Chinese Medicine Affiliated Hospital (Hunan Hospital of Integrated Traditional Chinese and Western Medicine), Changsha, 410006, China.
- School of Material Sciences and Engineering, Harbin Institute of Technology (Shenzhen), Shenzhen, 518055, China.
- Department of Microbiology, College of Life Sciences, Nankai University, Tianjin, 300071, China.
ORCID-Profile: Jiaheng Zhang
Förderung
- Shenzhen Science and Technology Innovation Committee
- National Natural Science Foundation of China
- Science and Technology Innovation Program of Hunan Province
Zitieren
APA
Deng, X., Bian, Q., Zhou, M., Xie, L., Zhang, J., Liu, T., Zhang, Y., Zhang, L., Zhang, J., & Bai, L. (2025). A Supramolecular Material for Controlling Kiwifruit Bacterial Canker. Advanced Science, 12(31). https://doi.org/10.1002/advs.202414752
Vancouver
Deng X, Bian Q, Zhou M, Xie L, Zhang J, Liu T, et al. A Supramolecular Material for Controlling Kiwifruit Bacterial Canker. Advanced Science. 2025;12(31). doi:10.1002/advs.202414752
BibTeX
@article{Deng2025,
author = {Deng, Xile and Bian, Qiang and Zhou, Mingqing and Xie, Le and Zhang, Jichuan and Liu, Tianqi and Zhang, Yizhuo and Zhang, Li and Zhang, Jiaheng and Bai, Lianyang},
title = {A Supramolecular Material for Controlling Kiwifruit Bacterial Canker},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {31},
doi = {10.1002/advs.202414752}
}
EUVIMED